Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment - PubMed (original) (raw)
Clinical Trial
Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment
N Andreasen et al. Neurosci Lett. 1999.
Abstract
We studied CSF-tau and CSF-Abeta42 in 16 patients with mild cognitive impairment (MCI) who at follow-up investigations 6-27 months later had progressed to Alzheimer's disease (AD) with dementia. For comparison, we studied 15 age-matched healthy individuals. At baseline, 14/16 (88%) of MCI patients had high CSF-tau and/or low CSF-Abeta42 levels. These findings show that these CSF-markers are abnormal before the onset of clinical dementia and that they may help to identify MCI patients that will develop AD. This is especially important when drugs with potential effects on the progression of AD will reach the clinical phase.
Similar articles
- Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.
Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A. Riemenschneider M, et al. Arch Neurol. 2002 Nov;59(11):1729-34. doi: 10.1001/archneur.59.11.1729. Arch Neurol. 2002. PMID: 12433260 - Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Hansson O, et al. Lancet Neurol. 2006 Mar;5(3):228-34. doi: 10.1016/S1474-4422(06)70355-6. Lancet Neurol. 2006. PMID: 16488378 - Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment.
Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K. Andreasen N, et al. Acta Neurol Scand Suppl. 2003;179:47-51. doi: 10.1034/j.1600-0404.107.s179.9.x. Acta Neurol Scand Suppl. 2003. PMID: 12603251 Clinical Trial. - Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.
Mattsson N, Lönneborg A, Boccardi M, Blennow K, Hansson O; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers. Mattsson N, et al. Neurobiol Aging. 2017 Apr;52:196-213. doi: 10.1016/j.neurobiolaging.2016.02.034. Neurobiol Aging. 2017. PMID: 28317649 Review.
Cited by
- Longitudinal CSF isoprostane and MRI atrophy in the progression to AD.
de Leon MJ, Mosconi L, Li J, De Santi S, Yao Y, Tsui WH, Pirraglia E, Rich K, Javier E, Brys M, Glodzik L, Switalski R, Saint Louis LA, Pratico D. de Leon MJ, et al. J Neurol. 2007 Dec;254(12):1666-75. doi: 10.1007/s00415-007-0610-z. Epub 2007 Nov 14. J Neurol. 2007. PMID: 17994313 - Beta-amyloid deposition and the aging brain.
Rodrigue KM, Kennedy KM, Park DC. Rodrigue KM, et al. Neuropsychol Rev. 2009 Dec;19(4):436-50. doi: 10.1007/s11065-009-9118-x. Epub 2009 Nov 12. Neuropsychol Rev. 2009. PMID: 19908146 Free PMC article. Review. - Revealing heterogeneity of brain imaging phenotypes in Alzheimer's disease based on unsupervised clustering of blood marker profiles.
Martí-Juan G, Sanroma G, Piella G; Alzheimer’s Disease Neuroimaging Initiative and the Alzheimer’s Disease Metabolomics Consortium. Martí-Juan G, et al. PLoS One. 2019 Mar 4;14(3):e0211121. doi: 10.1371/journal.pone.0211121. eCollection 2019. PLoS One. 2019. PMID: 30830917 Free PMC article. - Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.
Blennow K, Hampel H, Zetterberg H. Blennow K, et al. Neuropsychopharmacology. 2014 Jan;39(1):189-201. doi: 10.1038/npp.2013.154. Epub 2013 Jun 25. Neuropsychopharmacology. 2014. PMID: 23799530 Free PMC article. Review. - Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.
Hampel H, Shen Y, Walsh DM, Aisen P, Shaw LM, Zetterberg H, Trojanowski JQ, Blennow K. Hampel H, et al. Exp Neurol. 2010 Jun;223(2):334-46. doi: 10.1016/j.expneurol.2009.09.024. Epub 2009 Oct 6. Exp Neurol. 2010. PMID: 19815015 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical